Pulmonary arterial hypertension (PAH) is a rare, but devastating, disease characterized by progressive obliteration of the pulmonary microvasculature. Over the past decade, an increasing number of therapies targeting the prostacyclin, endothelin, and nitric oxide pathways have been shown to improve the symptoms of PAH and even slow disease progression. O'Callaghan and colleagues review the pharmacological agents currently available for the treatment of PAH and discuss potential novel therapeutic targets in this disease.
- Dermot S. O'Callaghan
- Laurent Savale
- Marc Humbert
